<table>
<thead>
<tr>
<th>Number</th>
<th>Objectives</th>
<th>Studies</th>
</tr>
</thead>
</table>
| 1.0    | Quantification of HIV Reservoirs and Their Decay on Standard Antiretroviral Therapy | A5248 (Raltegravir Viral Decay Study)  
A5249s (Raltegravir Viral Decay Dynamics Substudy)  
A5321 (ACTG HIV Reservoirs Cohort (AHRC))  
A5341s (A5321 Sampling Substudy)  
A5345 (HIV Rebound & Control Biomarkers)  
A5347s (A5345 Tissue Substudy)  
A5354 (Early ART in Acute HIV)  
NWCS 371 (Predictors of HIV-1 Rebound after Antiretroviral Treatment Discontinuation)  
NWCS 392 (IFN Stimulated Gene Expression and HIV-Specific T-cell Immunity)  
NWCS 394 (Inflammatory Determinants of the Latent HIV Reservoir: Impact of Tuberculosis, Geography and Sex)  
NWCS 416 (Phylogeographic Approach to Understand Viral Rebound and Cellular Re-Population)  
NWCS 419 (Expression of Immune Exhaustion Markers in Natural Killer Cells)  
NWCS 425 (Prevalence and Associated Factors of Residual Viremia in Participants with Long-Term Virological Suppression in Resource-Limited Countries)  
NWCS 436 (Phylogeographic Approach to Understand Viral Rebound and Cellular Re-population)  
NWCS 437 (Deep Sequencing Analyses of HIV-1 Env Genes to Identify Viral Replication in the CNS)  
NWCS 441 (Natural Killer Cell Repertoire and Function in HIV-1 Persistence)  
NWCS 443 (Effect of Declining Sex Hormones on HIV Persistence in HIV-infected Women on ART)  
NWCS 446 (Defining Relationship Between HIV-specific T-cells & the Viral Reservoir in A5321/A5341s)  
NWCS 456 (CD30 Expression and Viral Rebound)  
DACS 341 (Impact of Statin Use on Markers of HIV Persistence on ART) |
| 2.0    | Therapeutic HIV Vaccines to Control Viral Reservoirs | A5369 (p24CE Vaccine Study)  
A5374 (Therapeutic Vaccines on ART)  
NWCS 347 (Immunoglobulin Gene Variation in HIV-1 Controllers)  
NWCS 451 (Immune Responses to Conserved Elements in HIV-infected Eligible for Therapeutic Vaccine Trials) |
| 3.0    | Antiretroviral Therapy to Reduce Viral Reservoirs | A5308 (ART for HIV Controllers)  
NWCS 380 (Predictors of HIV Control after ATI) |
| 4.0    | Immune-based Therapies to Control Viral Reservoirs | A5337 (Sirolimus Study)  
A5342 (Impact of VRC01 on HIV Persistence)  
A5367 (Vedolizumab in ATI)  
A5370 (Anti-PD-1 Antibody in HIV-1)  
NWCS 391 (Mitochondrial Membrane Potential of Naive CD4+ T Cells Measured by Flow Cytometry)  
NWCS 397 (Evolution of HIV-1 under Interferon-alpha Tx in Vivo)  
NWCS 458 (IL-7 Administration and the HIV-1 Latent Reservoir) |
| 5.0    | Novel Strategies to Reduce Viral Reservoirs | A5315 (Romidepsin to Awaken HIV)  
A5337 (Sirolimus Study)  
A5366 (Effects of SERM and HDACi on HIV-1 Latency and RNA)  
DR 012 (Development of a Viral Dynamics Platform to Inform on Drug Development Decisions for HIV) |